Navigation Links
Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
Date:7/6/2012

lly from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2011, and Form 10-Q for the quarter ended March 31, 2012, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:

 James E. Fickenscher /
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
2. Auxilium Announces Appointments to Enhance Leadership Team
3. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
4. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
7. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
8. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
9. UAS Laboratories Presents about Probiotic Selection Criteria, at Scientific Conference
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Frost & Sullivan Presents 2012 Clinical Diagnostics Company of the Year Award to GenPath Diagnostics of BioReference Laboratories, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NY (PRWEB) September 18, 2014 Whitehouse ... negotiations with Salem Realty Group and has acquired an ... space within the Salem Executive Complex adjacent to its ... was held on Friday September 5th. Whitehouse Labs is ... the entire space specifically for package testing. The prime ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... publication of another peer-reviewed clinical study.    ... Multi-center Randomized Controlled Clinical Trial Evaluating the Use ... Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression ...
(Date:9/17/2014)... 17, 2014 Immunomic Therapeutics, Inc. announced ... (SBIR) grant to support the continued preclinical development of ... with approximately $255,000 over one year to conduct vaccine ... food allergy, affect over one million Americans and are ... Tree nut exposure is also a risk for peanut ...
Breaking Biology Technology:Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Oncothyreon Announces Proposed Public Offerings 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... for 2011, highlighting its continued focus on strong ... Company,s diabetes franchise, notably through advancing the investigational ... other value-driving development programs. Daniel M. Bradbury, president ...
... BioLife Solutions, Inc. (OTC Bulletin Board: BLFS ) ... and Chief Executive Officer Mike Rice, to summarize the continued ... strategic growth initiatives.   (Logo:   http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) ... of $575,000 for the fourth quarter of 2010, an increase ...
... The Jackson Laboratory (JAX), Sackler School of Graduate Biomedical Sciences ... a new mammalian genetics track for Ph.D. students. The joint ... and Tufts. Combining the faculty and resources of the genetics ... the faculty and resources at JAX, with its emphasis on ...
Cached Biology Technology:Amylin to Advance Key Value-Driving Opportunities in 2011 2Amylin to Advance Key Value-Driving Opportunities in 2011 3BioLife Solutions CEO Issues 2010 Corporate Update 2BioLife Solutions CEO Issues 2010 Corporate Update 3The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 2The Jackson Laboratory and Tufts University Announce New Ph.D. Track in Mammalian Genetics 3
(Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical ... the circulating protein apolipoprotein E, called apoE3, helps repair ... called apoE4, do not get the benefit of this ... , "We believe that we have identified one mechanism ... why a genetic variant, apoE4, is detrimental," said ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... is available in German . , ... , is able to rapidly ,and efficiently detoxify chemical ... the Tokyo subway attacks in 1995. A detailed understanding ... is ,necessary for efforts aiming to improve their properties. ...
... of Canada,s southern Rockies are a more distinct breed ... by University of Calgary researchers that is shedding light ... In a study published in the current issue of ... Design PhD candidate Byron Weckworth and his research group ...
... release is available in French . ... is pleased to announce that Concordia,s Centre for Structural ... research done by nine universities which are part of ... focusing on the conversion of agricultural waste into biofuel ...
Cached Biology News:Structure of enzyme against chemical warfare agents determined 2Mountain caribou's ancient ancestry revealed 2
... offers major advantages over other RNA precipitation methods ... or carbohydrates. It is the method of choice ... from RNA preparations. Note, LiCl precipitation may not ... If the RNA is to be used for ...
... Antifade Kit is an aqueous-based mounting reagent ... dyes. This formulation of antifade minimizes the ... Blue fluorophores that is often seen with ... available with the blue-fluorescent nucleic acid ...
in vitro Translation, Accessory Products...
Mouse Collagen IV...
Biology Products: